Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1997 1
1999 1
2000 1
2001 1
2002 2
2003 2
2004 4
2005 2
2006 8
2007 3
2008 15
2009 8
2010 6
2011 3
2012 2
2016 1
2017 4
2020 1
2021 2
2023 2
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association.
El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, Limacher MC, Manson JE, Stefanick ML, Allison MA; American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention; and Council on Cardiovascular and Stroke Nursing. El Khoudary SR, et al. Among authors: langer rd. Circulation. 2020 Dec 22;142(25):e506-e532. doi: 10.1161/CIR.0000000000000912. Epub 2020 Nov 30. Circulation. 2020. PMID: 33251828 Free article. Review.
Cardiovascular disease (CVD) is the leading cause of death in women, who have a notable increase in the risk for this disease after menopause and typically develop coronary heart disease several years later than men. This observation led to the hypothesis that the menop …
Cardiovascular disease (CVD) is the leading cause of death in women, who have a notable increase in the risk for this disease after menop …
2016 IMS Recommendations on women's midlife health and menopause hormone therapy.
Baber RJ, Panay N, Fenton A; IMS Writing Group. Baber RJ, et al. Climacteric. 2016 Apr;19(2):109-50. doi: 10.3109/13697137.2015.1129166. Epub 2016 Feb 12. Climacteric. 2016. PMID: 26872610
The International Menopause Society (IMS) has produced these new 2016 recommendations on women's midlife health and menopause hormone therapy (MHT) to help guide health-care professionals in optimizing their management of women in the menopause transition and …
The International Menopause Society (IMS) has produced these new 2016 recommendations on women's midlife health and menopause …
Hormone replacement therapy - where are we now?
Langer RD, Hodis HN, Lobo RA, Allison MA. Langer RD, et al. Climacteric. 2021 Feb;24(1):3-10. doi: 10.1080/13697137.2020.1851183. Epub 2021 Jan 6. Climacteric. 2021. PMID: 33403881 Review.
Hormone replacement therapy (HRT) was the standard of care for menopause management until 2002, when perceptions changed following release of the initial results from the Women's Health Initiative (WHI) trial. ...Clinically, HRT is usually initiated near menopause. …
Hormone replacement therapy (HRT) was the standard of care for menopause management until 2002, when perceptions changed following re …
Calcium plus vitamin D supplementation and the risk of fractures.
Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford SA, Black HR, Blanchette P, Bonds DE, Brunner RL, Brzyski RG, Caan B, Cauley JA, Chlebowski RT, Cummings SR, Granek I, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Johnson KC, Judd H, Kotchen JM, Kuller LH, Langer RD, Lasser NL, Limacher MC, Ludlam S, Manson JE, Margolis KL, McGowan J, Ockene JK, O'Sullivan MJ, Phillips L, Prentice RL, Sarto GE, Stefanick ML, Van Horn L, Wactawski-Wende J, Whitlock E, Anderson GL, Assaf AR, Barad D; Women's Health Initiative Investigators. Jackson RD, et al. Among authors: langer rd. N Engl J Med. 2006 Feb 16;354(7):669-83. doi: 10.1056/NEJMoa055218. N Engl J Med. 2006. PMID: 16481635 Free article. Clinical Trial.
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women's Health Initiative Steering Committee. Anderson GL, et al. Among authors: langer rd. JAMA. 2004 Apr 14;291(14):1701-12. doi: 10.1001/jama.291.14.1701. JAMA. 2004. PMID: 15082697 Free article. Clinical Trial.
The role of medications in successful aging.
Langer RD. Langer RD. Climacteric. 2021 Oct;24(5):505-512. doi: 10.1080/13697137.2021.1911991. Epub 2021 May 12. Climacteric. 2021. PMID: 33977831 Review.
The evidence base for HRT: what can we believe?
Langer RD. Langer RD. Climacteric. 2017 Apr;20(2):91-96. doi: 10.1080/13697137.2017.1280251. Epub 2017 Mar 10. Climacteric. 2017. PMID: 28281363 Review.
Prior to the unexpected early termination of the Women's Health Initiative (WHI) trial of continuous conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA), the prevailing view was that hormone replacement therapy (HRT) was a low-risk intervention with immediate …
Prior to the unexpected early termination of the Women's Health Initiative (WHI) trial of continuous conjugated equine estrogens (CEE) and m …
Progesterone from ovulatory menstrual cycles is an important cause of breast cancer.
Coelingh Bennink HJT, Schultz IJ, Schmidt M, Jordan VC, Briggs P, Egberts JFM, Gemzell-Danielsson K, Kiesel L, Kluivers K, Krijgh J, Simoncini T, Stanczyk FZ, Langer RD. Coelingh Bennink HJT, et al. Among authors: langer rd. Breast Cancer Res. 2023 May 30;25(1):60. doi: 10.1186/s13058-023-01661-0. Breast Cancer Res. 2023. PMID: 37254150 Free PMC article. Review.
We therefore postulate that P4 is an important factor in a woman's lifetime risk of developing BC, and that breast tumors arising during hormonal contraception or after menopause, with or without menopausal hormone therapy, are the consequence of the outgrowth of pre-exist …
We therefore postulate that P4 is an important factor in a woman's lifetime risk of developing BC, and that breast tumors arising during hor …
69 results